Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts resea...
Nanobac Pharmaceuticals reported revenue of $17,621 for fiscal year 2007, down 92.2% from fiscal year 2006, and net income of -$6.58 million. Its market capitalization was $124,752 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2007; market data as of October 9, 2026.
No profile data available.